Revised Korean medication algorithm for bipolar disorder

References

• American Psychiatric Association. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, 159(Suppl 4):1–50.
   Web of Science ®Google Scholar
• Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005; 66(Suppl 3)12–19
   PubMedGoogle Scholar
• Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. J Am Med Assoc 1994; 271: 918–924
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111–121
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, et al. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 2004; 65: 571–579
   PubMedGoogle Scholar
• Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005a; 162: 1351–1360
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005b; 162: 2152–2161
   PubMed Web of Science ®Google Scholar
• Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313–322
   PubMed Web of Science ®Google Scholar
• Forsthoff A, Grunze H, Seemüller F, Stampfer R, Dittmann S, Amann B, et al. Risperidone monotherapy in manic inpatients: an open label, multicentre trial. World J Biol Psychiatry 2007; 8: 256–261
   PubMed Web of Science ®Google Scholar
• Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108–111
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421–433
   PubMed Web of Science ®Google Scholar
• Gijsman HJ, Geddes JR. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537–1547
   PubMed Web of Science ®Google Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–173
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–441
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115–124
   PubMedGoogle Scholar
• Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003; 4: 5–13
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE, Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–1065
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Mendlwicz J, Calabrese JR, Fawcett J, Suppes T, Vestergaard PA, et al. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000; 59(Suppl 1)S31–37
   PubMedGoogle Scholar
• PE Keck, RH Perlis, MW Otto, Carpenter, D, R Ross, JP. Docherty. 2004. The expert consensus guideline series:treatment of bipolar disorder 2004, Postgrad Med Spec Report 1–116.
   Google Scholar
• Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006; 57: 133–136
   PubMed Web of Science ®Google Scholar
• Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?. Eur Arch Psychiatry Clin Neurosci 2000; 250: 57–68
   PubMed Web of Science ®Google Scholar
• Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust NZ J Psychiatry 2005; 39: 652–661
   PubMed Web of Science ®Google Scholar
• Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20: 163–168
   PubMed Web of Science ®Google Scholar
• Olfson M, Goldman HH. Psychiatric outpatient practice: patterns and policies. Am J Psychiatry 1992; 149: 1492–1498
   PubMed Web of Science ®Google Scholar
• Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549–550
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keck PE, Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301–310
   PubMed Web of Science ®Google Scholar
• Prien RF, Klett CJ, Caffey EM, Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420–425
   PubMed Web of Science ®Google Scholar
• Sachs GS, Koslow CL, Ghaemi SN. The treatment of bipolar depression. Bipolar Disord 2000a; 2: 256–260
   PubMed Web of Science ®Google Scholar
• GS Sachs, Printz, DJ, Kahn, DA, D Carpenter, JP. Docherty. 2000b. Expert consensus guideline series: medication treatment of bipolar disorder 2000, Postgrad Med Special Report 1–104.
   Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New Engl J Med 2007; 356(26)1711–1722
   PubMedGoogle Scholar
• Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870–886
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264–1266
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26: 530–536
   PubMed Web of Science ®Google Scholar
• The Executive Committee of the Korean Medication Algorithm Project for Bipolar Disorder. 2002. Korean medication algorithm for bipolar disorder. Seoul: Jungang Moonhwa.
   Google Scholar
• Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002a; 159: 1011–1017
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, Zarate CA, Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002b; 59: 62–69
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003a; 160: 1263–1271
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003b; 60: 1079–1088
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005; 7(Suppl 4)21–33
   PubMed Web of Science ®Google Scholar
• Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry 2007; 8: 4–11
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721–739
   PubMed Web of Science ®Google Scholar